Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases

Breast Cancer Research

Table 2 Summary table of CNS best response by composite criteria among evaluable patients

Response	All (n = 38)	Cohort 1 (HER2-negative) (n = 9)	Cohort 2 (HER2-positive) (n = 29)
Response	No. of patients (%)	No. of patients (%)	No. of patients (%)
CR	0 (0)	0 (0)	0 (0)
PR	24 (63)^a	5 (56)	19 (66)
SD > 24 weeks	2 (5)	0 (0)	2 (7)
SD < 24 weeks	5 (13)	0 (0)	5 (17)
PD^b	7 (18)	4 (44)	3 (10)
PD in CNS by radiographic criteria	1 (3)	0 (0)	1 (3)
Symptomatic deterioration	2 (5)	1 (11)	1 (3)
PD in non-CNS site(s)	4 (11)	3 (33)	1 (3)

^aTaking into account the two-stage design, the 95% CI for CNS ORR (n = 38) is 47 to 77%
^bPatients were considered to have progressed if any of the PD criteria were met. Each patient could also have been taken off study for meeting multiple PD criteria simultaneously
Abbreviations: CNS central nervous system, CR complete response, HER2 human epidermal growth factor receptor 2, PD progression of disease, PR partial response, SD stable disease

ISSN: 1465-542X